Dr. Gary H. Gibbons is the Director of the Cardiovascular Research Institute, an NIH/NHLBI-funded Research Center of Excellence, and Professor of Medicine at the Morehouse School of Medicine.
Dr. Gibbons earned his undergraduate degree from Princeton University and graduated magna cum laude from Harvard Medicial School in Boston in 1984. He completed
his residency and cardiology fellowship at the Harvard-affiliated Brigham & Women's Hospital in Boston. His research mentors include Victor Dzau, Thomas Smith, A. Clifford Barger, and Eugene Braunwald.
Dr. Gibbons has been selected as a Robert Wood Johnson Foundation Minority Faculty Development Awardee, a PEW Foundation Biomedical Scholar, and an Established Investigator of the American Heart Association (AHA). He was a member of the faculty at Stanford University from 1990 to 1996 and Harvard Medical School from 1996 to 1999 before becoming Director of the Morehouse Cardiovascular Research Institute in July 1999.
Dr. Gibbons serves on several editorial boards for journals in cardiovascular medicine as well as grant review committees for the NIH Juvenile Diabetes Foundation, and the AHA. Dr. Gibbons directos NIH-funded research in the fields of vascular-biology and the pathogenesis of vascular diseases. He is the author of over 70 reviews and original reports in the fields of vascular biology, gene therapy, and functional genomics in the cardiovascular sciences.
Dr. Gibbons' laboratory is currently focused on defining the molecular basis of vascular disease by integrating the DNA microarray technology with genetically engineered mouse models. In addition, he is collaborating with epidemiologists to define the molecular basis of ethnic disparities in cardiovascular disease based on the elucidation of interactions between the environment and disease-susceptibility genes.
Dr. Gibbons is actively engaged in academic-private industry partnerships that include services as a member of scientific advisory boards and consultant arrangements as well as research contracts. These arrangements include ongoing relationships with Millennium, Genzyme, and Novartis, as well as Merck, Parke-Davis, and Bristol-Meyes Squibb. He holds four U.S. patents, and has been involved in the technology transfer of licenses that have resulted in the generation of two start-up biotechnology companies.
